2,5-Dimethoxy-4-methylamphetamine (DOM), also known as STP (standing for "Serenity, Tranquility, and Peace" and other phrases), is a psychedelic drug of the phenethylamine, amphetamine, and DOx families. It has stimulant and antidepressant-like effects at low doses and hallucinogenic effects at high

How long does DOM last?

The total duration of DOM via oral is 12 hours to 16 hours. Onset typically occurs within 1 hour to 2 hours. Peak effects last 6 hours to 8 hours.

DOM — SubstanceWiki

SubstanceWiki

⌘K

DOM — SubstanceWiki

How It Feels

DOM arrives with the slow, inexorable certainty of a tide. For the first two to three hours, there is almost nothing to report beyond a mild body buzz, a slight tightening in the stomach, and perhaps a barely perceptible brightening of the visual field. The legendary patience required by DOM begins here, in this deceptive calm before the storm. By the third hour, the experience begins to gather momentum. A deep, resonant stimulation builds in the body, different from the sharp push of shorter-acting amphetamines. It feels tectonic, as though something enormous is shifting beneath the surface of consciousness.

When the peak finally arrives, typically between four and six hours after ingestion, it does so with a profundity that can overwhelm even experienced psychonauts. The visual world transforms utterly. Colors do not merely brighten; they appear to reveal hidden dimensions of themselves. The green of a tree contains infinite shades, each one distinct and meaningful. Geometric patterns of extraordinary complexity emerge from every surface, but they have a depth and solidity that sets them apart from lighter psychedelics. Patterns appear to exist not on surfaces but within them, as though the molecular structure of matter itself has become visible. The experience has been described as seeing the underlying code of reality, and while that metaphor sounds grandiose, it captures something essential about DOM's character.

Cognitively, DOM at its peak produces a state of profound, almost overwhelming depth. Thoughts are not merely accelerated but deepened. Questions about identity, existence, time, and meaning arise with an urgency and weight that can be transformative or terrifying. The emotional landscape is vast and unpredictable. Ecstatic wonder, existential dread, oceanic peace, and searing vulnerability may all visit within the same hour. The body, meanwhile, maintains its driven stimulation: elevated heart rate, jaw clenching, dilated pupils, and a warmth that radiates outward from the core. Movement feels both purposeful and slightly mechanical.

The extraordinary duration of DOM is its most defining characteristic. The peak alone can last six to eight hours, and the total experience spans fourteen to twenty hours, sometimes longer. The comedown is a marathon of slowly diminishing intensity, during which the mind gradually releases its grip on the deeper layers of perception. Colors remain vivid for hours after the visuals proper have faded. Sleep is impossible until the very end, and when it finally arrives, it is deep and heavy. The following day often carries a sense of having been somewhere genuinely profound, accompanied by a bone-deep tiredness that demands rest.

Subjective Effects

The effects listed below are based on the Subjective Effect Index (SEI), an open research literature based on anecdotal reports and personal analyses. They should be viewed with a healthy degree of skepticism. These effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects.

Physical Effects

Physical(10)

Appetite suppression— A distinct decrease in hunger and desire to eat, ranging from reduced interest in food to complete d...
Dehydration— A state of insufficient bodily hydration manifesting as persistent thirst, dry mouth, and physical d...
Increased heart rate— A noticeable acceleration of heartbeat that can range from a subtle awareness of one's pulse to a fo...
Nausea— An uncomfortable sensation of queasiness and stomach discomfort that may or may not lead to vomiting...
Physical euphoria— An intensely pleasurable bodily sensation that can manifest as waves of warmth, tingling electricity...
Pupil dilation— A visible enlargement of the pupil diameter (mydriasis) that can range from subtle widening to drama...
Seizure— Uncontrolled brain electrical activity causing convulsions and loss of consciousness -- a life-threa...
Stimulation— A state of heightened physical and mental energy characterized by increased wakefulness, elevated mo...
Teeth grinding— An involuntary clenching and rhythmic grinding of the jaw muscles, known clinically as bruxism, that...
Vasoconstriction— A narrowing of blood vessels throughout the body that produces sensations of cold extremities, tingl...

Tactile(1)

Tactile enhancement— The sense of touch becomes dramatically heightened, making physical contact feel intensely pleasurab...

Cognitive & Perceptual Effects

Visual(17)

After images— A visual phenomenon in which a faint, ghostly imprint of a previously viewed image persists in the v...
Autonomous entity— The perception of contact with seemingly sentient, independently acting beings that appear within ha...
Brightness alteration— Perceived increase or decrease in environmental brightness beyond actual illumination levels, common...
Colour enhancement— An intensification of the brightness, vividness, and saturation of colors in the external environmen...
Colour shifting— The visual experience of colors on objects and surfaces cycling through continuous, fluid transforma...
Depth perception distortions— Alterations in how the distance of objects within the visual field is perceived, causing layers of s...

Pharmacology

DOM is a selective partial agonist at the 5-HT2 receptor family. Its psychedelic effects are mediated by its agonistic properties at the 5-HT2A and 5-HT2B receptors, but less so on the 5-HT2C receptor. Due to its selectivity, DOM is often used in scientific research when studying the 5-HT2 receptor subfamily. DOM is a chiral molecule, and R-(-)-DOM is the more active enantiomer, functioning as a potent agonist of the serotonin family of receptors (mainly of the 5-HT2 subtype). However, the role of these interactions and how they result in the psychedelic experience continues to remain elusive.

The 2,6-dimethoxy positional isomer of DOM, known as Ψ-DOM, is also mentioned in PiHKAL as being active, as is the alpha-ethyl homologue Ariadne. Analogues where the methoxy groups at the 2,5- positions of the aromatic ring have been altered have also been synthesised and tested as part of an effort to identify the binding mode of DOM at the 5-HT2A receptor. Both the 2- and 5- O-desmethyl derivatives 2-DM-DOM and 5-DM-DOM, and the 2- and 5- ethyl analogues 2-Et-DOM and 5-Et-DOM have been tested, but in all cases were significantly less potent than the corresponding methoxy compound, showing the importance of the oxygen lone pairs in 5-HT2A binding.

There is a strong implication that some metabolic conversion occurs in the lung, and it is only after this that the truly active metabolite is available for central action. This is consistent with the relatively slow onset of effect, and the very long duration of action. Lithium is commonly prescribed in the treatment of bipolar disorder; however, there is a large body of anecdotal evidence that suggests taking it with psychedelics can significantly increase the risk of psychosis and seizures. As a result, this combination should be strictly avoided.

Tramadol]]** - Tramadol lowers the seizure threshold and psychedelics may act as triggers for seizures, particularly in those who are predisposed to them.
Stimulants]]** - Stimulants affect many parts of the brain. Combined with psychedelics, stimulation can turn into uncontrollable anxiety, panic, thought loops and paranoia. This interaction may cause elevated risk of psychosis.

Internationally, mescaline is part of the the Convention on Psychotropic Substances of 1971 as a Schedule I substance.

Australia: Australia has a blanket ban over all substituted phenethylamines including the entire DOx family.
Austria: DOM is illegal to possess, produce and sell under the SMG (Suchtmittelgesetz Österreich).
Brazil: Possession, production and sale is illegal as it is listed on Portaria SVS/MS nº 344 as "STP".
Belgium: DOM is a Schedule I drug.
Canada: DOM is a Schedule I drug.
Germany: DOM is controlled under Anlage I BtMG (Narcotics Act, Schedule I), former: Opiumgesetz (Opium Act) as of April 15, 1971. It is illegal to manufacture, possess, import, export, buy, sell, procure or dispense it without a license.
Latvia: DOM is a Schedule I controlled substance.
New Zealand: DOM is a Class A drug.
Switzerland: DOM is a controlled substance specifically named under Verzeichnis D.
United Kingdom: DOM is a Class A drug.
United States: DOM is a Schedule I drug.
Czech Republic: DOM is a Schedule I drug.
Responsible use
Psychedelics
Phenethylamines
DOx
DOC
DOI
2C-D
DOM (Wikipedia)
DOM (Erowid Vault)
DOM (PiHKAL / Isomer Design)
Discussion
The Big & Dandy DOM Thread (Bluelight)

Detection Methods

Urine Detection

DOM (4-methyl-2,5-dimethoxyamphetamine) is an amphetamine-derived psychedelic with a long duration of action and corresponding extended detection window. Due to its structural relationship to amphetamine, DOM and its metabolites may trigger presumptive positive results on standard amphetamine immunoassays. Urine detection windows are estimated at 2 to 4 days following ingestion when analyzed by immunoassay, and potentially longer with LC-MS/MS methods. The extended duration of action (up to 20 hours or more) means the body is eliminating parent compound and metabolites over a prolonged period.

Blood and Serum Detection

Blood detection windows for DOM are approximately 12 to 36 hours after oral ingestion, reflecting the compound's long pharmacological half-life. Peak plasma concentrations occur 2 to 4 hours post-ingestion. The slow offset of effects correlates with sustained measurable blood concentrations. LC-MS/MS provides the most sensitive and specific blood analysis.

Standard Drug Panel Inclusion

DOM is NOT specifically listed on standard 5-panel, 10-panel, or 12-panel drug screens. However, unlike most psychedelics, DOx-series amphetamines may cross-react with amphetamine immunoassays due to their intact amphetamine backbone. A presumptive positive for amphetamine on initial screening is a realistic possibility. On confirmatory testing by GC-MS or LC-MS/MS, the result would not confirm as amphetamine or methamphetamine, and would be reported as negative unless the laboratory specifically includes DOx compounds in their confirmatory panel. Most routine clinical laboratories do not test for DOx amphetamines.

Confirmatory Methods

Definitive identification of DOM requires GC-MS or LC-MS/MS with reference standards specific to DOx compounds. The amphetamine backbone makes GC-MS analysis straightforward without derivatization in most cases. Some forensic toxicology laboratories include DOx amphetamines in extended novel psychoactive substance panels. The relatively long detection window compared to other psychedelics provides a larger sampling window for confirmatory testing.

Reagent Testing (Harm Reduction)

The Marquis reagent produces variable color reactions with DOx amphetamines, ranging from orange-brown to olive-green depending on the specific compound. The Mecke reagent may produce blue-green to brown reactions. The Mandelin reagent typically shows green to brown. Critically, the Ehrlich reagent shows NO reaction with DOx amphetamines, which distinguishes them from lysergamides and tryptamines. Because DOx compounds are sometimes sold on blotter paper mimicking LSD, the Ehrlich test is an essential safety tool: absence of a purple reaction on blotter strongly suggests the substance is not LSD and may be a DOx compound or NBOMe. Given the very long duration of DOx compounds (12-24+ hours), correct identification prior to ingestion is important for safety planning.

Interactions

Substance	Status	Note
2-Aminoindane	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
2-FA	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
2-FEA	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
2-FMA	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
2,5-DMA	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
2C-H	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
3-FA	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
3-FEA	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
3-FMA	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
3-FPM	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
3-MMC	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
3,4-CTMP	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
4-FA	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
4-FMA	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
4-MMC	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
4F-EPH	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
4F-MPH	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
5-APB	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
5F-AKB48	Caution	Cannabis can unpredictably intensify psychedelic effects and increase anxiety
5F-PB-22	Caution	Cannabis can unpredictably intensify psychedelic effects and increase anxiety
6-APDB	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
8-Chlorotheophylline	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
A-PHP	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
A-PVP	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
AB-FUBINACA	Caution	Cannabis can unpredictably intensify psychedelic effects and increase anxiety
Adrafinil	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Amphetamine	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Anandamide	Caution	Cannabis can unpredictably intensify psychedelic effects and increase anxiety
APICA	Caution	Cannabis can unpredictably intensify psychedelic effects and increase anxiety
Armodafinil	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Atropa belladonna	Caution	Unpredictable compounding of hallucinogenic effects with anticholinergic delirium
Benzydamine	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Bromantane	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Butylone	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Caffeine	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Cannabidiol	Caution	Cannabis can unpredictably intensify psychedelic effects and increase anxiety
Cannabis	Caution	Cannabis can unpredictably intensify psychedelic effects and increase anxiety
Cocaine	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Cyclazodone	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Datura	Caution	Unpredictable compounding of hallucinogenic effects with anticholinergic delirium
Desoxypipradrol	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Dextroamphetamine	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Dichloropane	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Diphenhydramine	Caution	Unpredictable compounding of hallucinogenic effects with anticholinergic delirium
Ephedrine	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Ephylone	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
ETH-CAT	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Ethylone	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Ethylphenidate	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Fenethylline	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Harmala alkaloid	Caution	MAOIs dramatically potentiate psychedelics; drastically reduce dose and exercise extreme caution
Hexedrone	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Isopropylphenidate	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
JWH-018	Caution	Cannabis can unpredictably intensify psychedelic effects and increase anxiety
JWH-073	Caution	Cannabis can unpredictably intensify psychedelic effects and increase anxiety
Kratom	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Lisdexamfetamine	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
MAOI	Caution	MAOIs dramatically potentiate psychedelics; drastically reduce dose and exercise extreme caution
MCPP	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
MDA	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
MDMA	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
MDPV	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Mephedrone	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Methamphetamine	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Methcathinone	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Methiopropamine	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Methylnaphthidate	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Methylone	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Methylphenidate	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Mexedrone	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Mirtazapine	Caution	Unpredictable compounding of hallucinogenic effects with anticholinergic delirium
Modafinil	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Myristicin	Caution	Unpredictable compounding of hallucinogenic effects with anticholinergic delirium
N-Ethylhexedrone	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
N-Methylbisfluoromodafinil	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
NEP	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Nicotine	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
NM-2-AI	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Oxiracetam	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Peganum harmala	Caution	MAOIs dramatically potentiate psychedelics; drastically reduce dose and exercise extreme caution
Pentedrone	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Phenylpiracetam	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Rhodiola Rosea	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
1,3-Butanediol	Low Risk & Synergy	Cross-tolerance exists; effects compound
1B-LSD	Low Risk & Synergy	Cross-tolerance exists; effects compound
1cP-AL-LAD	Low Risk & Synergy	Cross-tolerance exists; effects compound
1cP-LSD	Low Risk & Synergy	Cross-tolerance exists; effects compound
1cP-MiPLA	Low Risk & Synergy	Cross-tolerance exists; effects compound
1P-ETH-LAD	Low Risk & Synergy	Cross-tolerance exists; effects compound
1P-LSD	Low Risk & Synergy	Cross-tolerance exists; effects compound
1V-LSD	Low Risk & Synergy	Cross-tolerance exists; effects compound
2-Fluorodeschloroketamine	Low Risk & Synergy	Produces unique synergistic effects; often combined
25B-NBOH	Low Risk & Synergy	Cross-tolerance exists; effects compound
25B-NBOMe	Low Risk & Synergy	Cross-tolerance exists; effects compound
25C-NBOH	Low Risk & Synergy	Cross-tolerance exists; effects compound
25C-NBOMe	Low Risk & Synergy	Cross-tolerance exists; effects compound
25D-NBOMe	Low Risk & Synergy	Cross-tolerance exists; effects compound
25E-NBOH	Low Risk & Synergy	Cross-tolerance exists; effects compound
25I-NBOH	Low Risk & Synergy	Cross-tolerance exists; effects compound
25I-NBOMe	Low Risk & Synergy	Cross-tolerance exists; effects compound
25N-NBOMe	Low Risk & Synergy	Cross-tolerance exists; effects compound
2C-B	Low Risk & Synergy	Cross-tolerance exists; effects compound
2C-B-FLY	Low Risk & Synergy	Cross-tolerance exists; effects compound
2C-C	Low Risk & Synergy	Cross-tolerance exists; effects compound
2C-D	Low Risk & Synergy	Cross-tolerance exists; effects compound
2C-E	Low Risk & Synergy	Cross-tolerance exists; effects compound
2C-I	Low Risk & Synergy	Cross-tolerance exists; effects compound
2C-P	Low Risk & Synergy	Cross-tolerance exists; effects compound
2C-T	Low Risk & Synergy	Cross-tolerance exists; effects compound
2C-T-2	Low Risk & Synergy	Cross-tolerance exists; effects compound
2C-T-21	Low Risk & Synergy	Cross-tolerance exists; effects compound
2C-T-7	Low Risk & Synergy	Cross-tolerance exists; effects compound
3-Cl-PCP	Low Risk & Synergy	Produces unique synergistic effects; often combined
3-HO-PCE	Low Risk & Synergy	Produces unique synergistic effects; often combined
3-HO-PCP	Low Risk & Synergy	Produces unique synergistic effects; often combined
3-MeO-PCE	Low Risk & Synergy	Produces unique synergistic effects; often combined
3-MeO-PCMo	Low Risk & Synergy	Produces unique synergistic effects; often combined
3-MeO-PCP	Low Risk & Synergy	Produces unique synergistic effects; often combined
3C-E	Low Risk & Synergy	Cross-tolerance exists; effects compound
3C-P	Low Risk & Synergy	Cross-tolerance exists; effects compound
4-AcO-DET	Low Risk & Synergy	Cross-tolerance exists; effects compound
4-AcO-DiPT	Low Risk & Synergy	Cross-tolerance exists; effects compound
4-AcO-DMT	Low Risk & Synergy	Cross-tolerance exists; effects compound
4-AcO-MET	Low Risk & Synergy	Cross-tolerance exists; effects compound
4-AcO-MiPT	Low Risk & Synergy	Cross-tolerance exists; effects compound
4-HO-DET	Low Risk & Synergy	Cross-tolerance exists; effects compound
4-HO-DiPT	Low Risk & Synergy	Cross-tolerance exists; effects compound
4-HO-DPT	Low Risk & Synergy	Cross-tolerance exists; effects compound
4-HO-EPT	Low Risk & Synergy	Cross-tolerance exists; effects compound
4-HO-MET	Low Risk & Synergy	Cross-tolerance exists; effects compound
4-HO-MiPT	Low Risk & Synergy	Cross-tolerance exists; effects compound
4-HO-MPT	Low Risk & Synergy	Cross-tolerance exists; effects compound
4-MeO-PCP	Low Risk & Synergy	Produces unique synergistic effects; often combined
5-MeO-DALT	Low Risk & Synergy	Cross-tolerance exists; effects compound
5-MeO-DiBF	Low Risk & Synergy	Cross-tolerance exists; effects compound
5-MeO-DiPT	Low Risk & Synergy	Cross-tolerance exists; effects compound
5-MeO-DMT	Low Risk & Synergy	Cross-tolerance exists; effects compound
5-MeO-MiPT	Low Risk & Synergy	Cross-tolerance exists; effects compound
6-APB	Low Risk & Synergy	Cross-tolerance exists; effects compound
AL-LAD	Low Risk & Synergy	Cross-tolerance exists; effects compound
ALD-52	Low Risk & Synergy	Cross-tolerance exists; effects compound
Allylescaline	Low Risk & Synergy	Cross-tolerance exists; effects compound
Ayahuasca	Low Risk & Synergy	Cross-tolerance exists; effects compound
Bromo-DragonFLY	Low Risk & Synergy	Cross-tolerance exists; effects compound
Bufotenin	Low Risk & Synergy	Cross-tolerance exists; effects compound
Deschloroketamine	Low Risk & Synergy	Produces unique synergistic effects; often combined
DET	Low Risk & Synergy	Cross-tolerance exists; effects compound
Dextromethorphan	Low Risk & Synergy	Produces unique synergistic effects; often combined
Diphenidine	Low Risk & Synergy	Produces unique synergistic effects; often combined
DiPT	Low Risk & Synergy	Cross-tolerance exists; effects compound
DMT	Low Risk & Synergy	Cross-tolerance exists; effects compound
DOB	Low Risk & Synergy	Cross-tolerance exists; effects compound
DOC	Low Risk & Synergy	Cross-tolerance exists; effects compound
DOI	Low Risk & Synergy	Cross-tolerance exists; effects compound
DPT	Low Risk & Synergy	Cross-tolerance exists; effects compound
Efavirenz	Low Risk & Synergy	Cross-tolerance exists; effects compound
Ephenidine	Low Risk & Synergy	Produces unique synergistic effects; often combined
EPT	Low Risk & Synergy	Cross-tolerance exists; effects compound
Escaline	Low Risk & Synergy	Cross-tolerance exists; effects compound
ETH-LAD	Low Risk & Synergy	Cross-tolerance exists; effects compound
HXE	Low Risk & Synergy	Produces unique synergistic effects; often combined
Ibogaine	Low Risk & Synergy	Cross-tolerance exists; effects compound
Inhalants	Low Risk & Synergy	Produces unique synergistic effects; often combined
Ketamine	Low Risk & Synergy	Produces unique synergistic effects; often combined
LAE-32	Low Risk & Synergy	Cross-tolerance exists; effects compound
LSA	Low Risk & Synergy	Cross-tolerance exists; effects compound
LSD	Low Risk & Synergy	Cross-tolerance exists; effects compound
LSM-775	Low Risk & Synergy	Cross-tolerance exists; effects compound
LSZ	Low Risk & Synergy	Cross-tolerance exists; effects compound
Memantine	Low Risk & Synergy	Produces unique synergistic effects; often combined
Mescaline	Low Risk & Synergy	Cross-tolerance exists; effects compound
MET	Low Risk & Synergy	Cross-tolerance exists; effects compound
Methallylescaline	Low Risk & Synergy	Cross-tolerance exists; effects compound
Methoxetamine	Low Risk & Synergy	Produces unique synergistic effects; often combined
Methoxphenidine	Low Risk & Synergy	Produces unique synergistic effects; often combined
MiPLA	Low Risk & Synergy	Cross-tolerance exists; effects compound
MiPT	Low Risk & Synergy	Cross-tolerance exists; effects compound
MPT	Low Risk & Synergy	Cross-tolerance exists; effects compound
MXiPr	Low Risk & Synergy	Produces unique synergistic effects; often combined
Nitrous	Low Risk & Synergy	Produces unique synergistic effects; often combined
O-PCE	Low Risk & Synergy	Produces unique synergistic effects; often combined
PARGY-LAD	Low Risk & Synergy	Cross-tolerance exists; effects compound
PCE	Low Risk & Synergy	Produces unique synergistic effects; often combined
PCP	Low Risk & Synergy	Produces unique synergistic effects; often combined
PRO-LAD	Low Risk & Synergy	Cross-tolerance exists; effects compound
Psilocybin Mushrooms	Low Risk & Synergy	Cross-tolerance exists; effects compound
Codeine	Low Risk & No Synergy	No significant pharmacological interaction; opioids may slightly dull the psychedelic experience
Fentanyl	Low Risk & No Synergy	No significant pharmacological interaction; opioids may slightly dull the psychedelic experience
Heroin	Low Risk & No Synergy	No significant pharmacological interaction; opioids may slightly dull the psychedelic experience
Morphine	Low Risk & No Synergy	No significant pharmacological interaction; opioids may slightly dull the psychedelic experience
Oxycodone	Low Risk & No Synergy	No significant pharmacological interaction; opioids may slightly dull the psychedelic experience
Alcohol	Low Risk & Decrease	Depressants dull psychedelic effects; benzodiazepines are commonly used as trip-killers
Alprazolam	Low Risk & Decrease	Depressants dull psychedelic effects; benzodiazepines are commonly used as trip-killers
Clonazepam	Low Risk & Decrease	Depressants dull psychedelic effects; benzodiazepines are commonly used as trip-killers
Diazepam	Low Risk & Decrease	Depressants dull psychedelic effects; benzodiazepines are commonly used as trip-killers
GHB	Low Risk & Decrease	Depressants dull psychedelic effects; benzodiazepines are commonly used as trip-killers
Lorazepam	Low Risk & Decrease	Depressants dull psychedelic effects; benzodiazepines are commonly used as trip-killers

Showing 197 key interactions out of 240 total.

History

DOM was first synthesized and tested in 1963 by Alexander Shulgin, who was investigating the effect of 4-position substitutions on psychedelic amphetamines.

This is one of the last of the experimental compounds within the phenethylamine family on which any animal toxicity studies were performed prior to human studies. The LD50 of DOM is between 100 - 125 mg/kg for a mouse. An effective dose in a human of 2 mg (for an 80 kg man) is equivalent to 25 μg/kg.

As with DOI, the presence of a heavy atom, the bromine atom, in DOB makes the radioactive isotope labelled material a powerful research tool. However, the role of these interactions and how they result in the psychedelic experience continues to remain elusive.

Tramadol]]** - Tramadol lowers the seizure threshold and psychedelics may act as triggers for seizures, particularly in those who are predisposed to them.
Stimulants]]** - Stimulants affect many parts of the brain. Combined with psychedelics, stimulation can turn into uncontrollable anxiety, panic, thought loops and paranoia. This interaction may cause elevated risk of psychosis.

Internationally, mescaline is part of the the Convention on Psychotropic Substances of 1971 as a Schedule I substance.

Australia: Australia has a blanket ban over all substituted phenethylamines including the entire DOx family.
Austria: DOM is illegal to possess, produce and sell under the SMG (Suchtmittelgesetz Österreich).
Brazil: Possession, production and sale is illegal as it is listed on Portaria SVS/MS nº 344 as "STP".
Belgium: DOM is a Schedule I drug.
Canada: DOM is a Schedule I drug.
Germany: DOM is controlled under Anlage I BtMG (Narcotics Act, Schedule I), former: Opiumgesetz (Opium Act) as of April 15, 1971. It is illegal to manufacture, possess, import, export, buy, sell, procure or dispense it without a license.
Latvia: DOM is a Schedule I controlled substance.
New Zealand: DOM is a Class A drug.
Switzerland: DOM is a controlled substance specifically named under Verzeichnis D.
United Kingdom: DOM is a Class A drug.
United States: DOM is a Schedule I drug.
Czech Republic: DOM is a Schedule I drug.
Responsible use
Psychedelics
Phenethylamines
DOx
DOC
DOI
2C-D
DOM (Wikipedia)
DOM (Erowid Vault)
DOM (PiHKAL / Isomer Design)
Discussion
The Big & Dandy DOM Thread (Bluelight)

Toxicity & Safety

Further information: Research chemicals § Toxicity and harm potential, and Responsible use § Hallucinogens The toxicity and long-term health effects of recreational DOM use do not seem to have been studied in any scientific context and the exact toxic dose is unknown.

Anecdotal evidence suggests that there are no negative health effects attributed to simply trying the substance by itself at low to moderate doses and using it very sparingly (but nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.

It is strongly recommended that one use harm reduction practices when using this substance.

Tolerance and addiction potential

DOM is not habit-forming and the desire to use it can decrease with use. It is most often self-regulating.

Tolerance to the effects of DOM is built almost immediately after ingestion. After that, it takes about 3 days for the tolerance to be reduced to half and 7 days to be back at baseline (in the absence of further consumption). DOM presents cross-tolerance with all psychedelics, meaning that after the consumption of DOM all psychedelics will have a reduced effect.

Overdose

The risk of a DOx overdose is present starting in or past the heavy dose range with sensitive people, or when a DOx is mixed with other substances, particularly stimulants or MAOIs. Non-oral routes also seem to exhibit a higher chance of overdosing, perhaps owing to differences in bioavailability, potency and unpredictability of dosage and effects. The effects of a DOx overdose typically include bizarre, delusional and sometimes violent behavior, amnesia, numbness, confusion and anxiety. The user may not be able to communicate and can be severely agitated. At appropriately high doses, more serious side effects such as psychosis, panic attacks and seizures which in turn further affect a dangerously elevated heart rate, blood pressure and vasoconstriction may occur. Severe vasoconstriction typically develops to its peak several hours into the intoxication and may require medical assistance if blood flow is significantly cut off for extended periods of time.

In the event of an overdose, benzodiazepines or antipsychotics can be administered to mitigate the hyperagitative effects. A powerful vasodilator may also need to be administered to prevent a hypertensive emergency, or in more serious cases, necrosis, organ failure and death from the resulting hypoxia. As a result, emergency medical services should always be sought in the event of a DOx overdose.

Dangerous interactions

Warning: Many psychoactive substances that are reasonably safe to use on their own can suddenly become dangerous and even life-threatening when combined with certain other substances. The following list provides some known dangerous interactions (although it is not guaranteed to include all of them).

Always conduct independent research (e.g. Google, DuckDuckGo, PubMed) to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from TripSit.

Lithium: Lithium is commonly prescribed in the treatment of bipolar disorder; however, there is a large body of anecdotal evidence that suggests taking it with psychedelics can significantly increase the risk of psychosis and seizures. As a result, this combination should be strictly avoided.
Tramadol - Tramadol lowers the seizure threshold and psychedelics may act as triggers for seizures, particularly in those who are predisposed to them.
Stimulants - Stimulants affect many parts of the brain. Combined with psychedelics, stimulation can turn into uncontrollable anxiety, panic, thought loops and paranoia. This interaction may cause elevated risk of psychosis.

Addiction Potential

not habit-forming

Overdose Information

Overdose -Lithium**: Lithium is commonly prescribed in the treatment of bipolar disorder; however, there is a large body of anecdotal evidence that suggests taking it with psychedelics can significantly increase the risk of psychosis and seizures. As a result, this combination should bestrictly avoided.

Tramadol]]** - Tramadol lowers the seizure threshold and psychedelics may act as triggers for seizures, particularly in those who are predisposed to them.
Stimulants]]** - Stimulants affect many parts of the brain. Combined with psychedelics, stimulation can turn into uncontrollable anxiety, panic, thought loops and paranoia. This interaction may cause elevated risk of psychosis.

Internationally, mescaline is part of the the Convention on Psychotropic Substances of 1971 as a Schedule I substance.

Australia: Australia has a blanket ban over all substituted phenethylamines including the entire DOx family.
Austria: DOM is illegal to possess, produce and sell under the SMG (Suchtmittelgesetz Österreich).
Brazil: Possession, production and sale is illegal as it is listed on Portaria SVS/MS nº 344 as "STP".
Belgium: DOM is a Schedule I drug.
Canada: DOM is a Schedule I drug.
Germany: DOM is controlled under Anlage I BtMG (Narcotics Act, Schedule I), former: Opiumgesetz (Opium Act) as of April 15, 1971. It is illegal to manufacture, possess, import, export, buy, sell, procure or dispense it without a license.
Latvia: DOM is a Schedule I controlled substance.
New Zealand: DOM is a Class A drug.
Switzerland: DOM is a controlled substance specifically named under Verzeichnis D.
United Kingdom: DOM is a Class A drug.
United States: DOM is a Schedule I drug.
Czech Republic: DOM is a Schedule I drug.
Responsible use
Psychedelics
Phenethylamines
DOx
DOC
DOI
2C-D
DOM (Wikipedia)
DOM (Erowid Vault)
DOM (PiHKAL / Iso

DOM

Quick Dosage

Dosage

oral

Duration

oral

How It Feels

Subjective Effects

Physical Effects

Physical(10)

Tactile(1)

Cognitive & Perceptual Effects

Visual(17)

Pharmacology

Detection Methods

Urine Detection

Blood and Serum Detection

Standard Drug Panel Inclusion

Confirmatory Methods

Reagent Testing (Harm Reduction)

Interactions

History

Harm Reduction

Toxicity & Safety

Addiction Potential

Overdose Information

Tolerance

Cross-tolerances

Legal Status

Experience Reports (3)

Tips (6)

Community Discussions (2)

See Also

Similar by Effects

Same Class

References (6)

Frequently Asked Questions

Cognitive(15)

Auditory(3)

Multi-sensory(1)

Transpersonal(4)